Bhaswati Sarcar1, Xinqun Li2, Jason B. Fleming1*

1Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, FL, USA

2Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, TX, USA

The extracellular matrix (ECM) in the tumor microenvironment (TME) has gained considerable interest in recent years as a crucial component in fundamental cellular processes and provides novel therapeutic targets. Lumican is a class II small leucine-rich proteoglycan with a key role in ECM organization and modulation of biological functions dependent on tumor type, abundance, and stage of disease. The presence of stromal lumican in the ECM surrounding pancreatic ductal adenocarcinoma (PDAC) inhibits cancer cell replication and is associated with improved patient outcomes after multimodal therapies. In this mini-review, we re-present our novel findings describing how hypoxia (1% O2) within the TME influences stromal lumican expression and secretion. We observed that hypoxia specifically inhibited lumican expression and secretion post-transcriptionally only from pancreatic stellate cells. Hypoxia-induced increased lactate production did not influence lumican expression. Notably, autophagy was induced by hypoxia in ex vivo cultures of patient-derived primary PDAC xenograft and pancreatic stellate cells; however, the cancer cells remain unaffected. Moreover, hypoxia-inducible factor (HIF)-1α expression or inhibition of AMP-regulated protein kinase (AMPK) activation within hypoxic stellate cells restored lumican expression levels. Interestingly, AMPK inhibition attenuated hypoxia-reduced phosphorylation of the mTOR/p70S6K/4EBP signaling pathway. The aim of this mini-review is to summarize our recent publication that hypoxia reduces stromal lumican in PDAC through autophagy-mediated degradation and reduction in protein synthesis within pancreatic cancer stellate cells. This may provide another plausible mechanism by which hypoxia-induced stromal autophagy leads to cancer growth.

DOI: 10.29245/2578-2967/2019/1.1165 View / Download Pdf

Steven S. Coughlin1,2*, Lee Caplan3, Jessica Lynn Stewart4, Lufei Young5

1Department of Population Health Sciences, Medical College of Georgia, Augusta University, Augusta, GA

2Research Service, Charlie Norwood Veterans Administration Medical Center, Augusta, GA

3Morehouse College of Medicine, Department of Community Health and Preventive Medicine, Atlanta, GA

4College of Allied Health Sciences, Augusta University, Augusta, GA

5College of Nursing, Augusta University, Augusta, GA

Although they have been widely studied, important questions remain about the impact of breast cancer survivorship care plans on improving health outcomes. The goal of this article was to review published studies on the impact of cancer survivorship care plans on health outcomes and health care delivery among breast cancer survivors. A total of 111 article citations were identified in PubMed and non-duplicates in CINAHL. After screening the abstracts or full texts of these articles and reviewing the references of previous review articles, 7 studies met the eligibility criteria. All of the studies had a randomized controlled design. Early trials of the efficacy of breast cancer survivorship care plans generally showed little or no improvement in health outcomes. The positive findings of recent studies suggest that survivorship care interventions that empower and activate patients to self-manage their follow-up care and improve patient-provider communication may be especially promising.

DOI: 10.29245/2578-2967/2019/1.1166 View / Download Pdf

Miao Guo1, Wei Wu5, Wei Liu2, 3*, Fu Ren2, 3, 4#

1Department of Clinical Laboratory, the First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121001, Liaoning, China

2Institute of Biological Anthropology, Jinzhou Medical University, No.40, Section 3, Songpo Road, Linghe District, Jinzhou 121001, Liaoning, China

3Liaoning Province Key Laboratory of Chinese Physical Characteristics Research (LPKL-CPCR), Jinzhou 121001, Liaoning, China

4Department of Anatomy, College of Basic Medical Sciences of Jinzhou Medical University, Jinzhou 121001, Liaoning, China

5School of Humanities and Management, Jinzhou Medical University, Jinzhou, Liaoning, China 121001

Glycoprotein A Repetitions Predominant (GARP), also known as leucine-rich repeats containing 32 (LRRC32), is a transmembrane protein that presents latent TGF-β1 on the surface of regulatory T cells (Tregs) and modulates its activation in tumor immunosuppressive environment. Tregs are immunosuppressive immune cells that play an important role in tumor development and progression. Inhibition of Treg function is considered to be an effective strategy for antitumor therapy. In addition to its expression in Tregs, GARP has been recently found to be highly expressed in a few types of human solid tumor tissues, yet the role of its expression in tumor tissues or cells remains unknown. Most previous studies on GARP have focused on GARP function in Tregs and the role of GARP in latent TGF-β1 activation. The present review provides an up to date overview of GARP expression and its potential role in tumor cells and tissues.

DOI: 10.29245/2578-2967/2019/1.1164 View / Download Pdf

Efrossini D. Patsou1, George T. Alexias1, Fotios G. Anagnostopoulos1, Michalis V. Karamouzis2*

1Department of Psychology, Panteion University of Social and Political Sciences, Athens, Greece

2Medical School, National and Kapodistrian University of Athens, Athens, Greece

Breast cancer is the most common cancer affecting women worldwide. Women have many disturbing feelings and psychological side effects during diagnosis, treatment and survivorship which include depression, anxiety, low self-esteem and poor quality of life. The aim of the study was to examine the associations between physical activity, global health, quality of life, depressive symptoms, self-esteem, and anxiety in breast cancer survivors after finishing cancer treatment and through survivorship. Demographic variables such as marital status, education, and income, as well as cancer stage and level of physical activity were tested as predictors of depressive mood, anxiety, self-esteem and quality of life in 171 Greek breast cancer survivors.

We are presenting a commentary on the paper in order to highlight the most important conclusions of the study and suggest areas for further investigation.

DOI: 10.29245/2578-2967/2019/1.1161 View / Download Pdf

Franziska Singer1,2, Daniel J. Stekhoven1,2*

1NEXUS Personalized Health Technologies, ETH Zurich, Otto-Stern-Weg 7, 8093, Zurich, Switzerland

2SIB Swiss Institute of Bioinformatics, 4058 Basel, Switzerland

DOI: 10.29245/2578-2967/2019/1.1163 View / Download Pdf

Yingtian Wang, Ying Zhang, Jie Liu, Huiting Fan, Xueqian Wang, Hong-sheng Lin*

Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China

DOI: 10.29245/2578-2967/2019/1.1138 View / Download Pdf

Shinji Atagi

Kinki-chuo Chest Medical Center, Osaka, Japan

As of now, concurrent chemoradiotherapy is the treatment of choice for locally advanced stage III non-small cell lung cancer (NSCLC). Older adults continue to be underrepresented in clinical trials, and studies designed specifically for this age group are rare. Prospective elderly-specific trials for locally advanced stage III NSCLC provide little evidence. Older patients are more susceptible to adverse events. A key question is whether elderly patients can receive the same treatments and derive the same benefit as their younger counterparts. The JCOG0301 demonstrated the clinically significant benefits of concurrent daily low-dose carboplatin and thoracic radiotherapies in elderly patients in comparison with those of radiotherapy alone. Recently, durvalumab therapy improved the progression-free survival of patients with unresectable stage III NSCLC whose disease had not progressed after concurrent chemoradiotherapy. Therefore, immune checkpoint inhibitors will also play an increasing role for elderly patients with stage III NSCLC. There are great differences between elderly individuals. Geriatric assessment is recommended to be incorporated in clinical trials. Furthermore, pragmatic clinical trials are required to establish clinical evidence for older patients with a broad range of conditions.

DOI: 10.29245/2578-2967/2019/1.1148 View / Download Pdf

Steven S. Coughlin1,2*, Lee Caplan3, Lufei Young4

1Department of Population Health Sciences, Medical College of Georgia, Augusta University, Augusta, GA

2Research Service, Charlie Norwood Veterans Affairs Medical Center, Augusta, GA

3Morehouse College of Medicine, Department of Community Health and Preventive Medicine, Atlanta, GA

4College of Nursing, Augusta University, Augusta, GA

Background: Patient portals and other Internet-based technologies have been increasingly used to improve cancer care coordination. Patient portals may introduce special considerations in oncology populations where longitudinal outpatient care is often more intensive than in most other specialties.

Methods: This article, which is based upon bibliographic searches in PubMed, reviews the literature on web portal use by cancer patients. Articles published in English from 2000 to August 2018 were identified using the following MeSH search terms and Boolean algebra commands: web portal AND cancer. Information obtained from bibliographic searches (title and topic of article, information in abstract, and keywords) was used to determine whether to retain each article identified in this way.

Results: A total of 263 article citations were identified in the bibliographic searches. Of these, 10 met the eligibility criteria. A variety of study designs were used including focus groups, usability testing, in-person interviews, questionnaire surveys, retrospective cohort, and non-randomized trial. Cancer patients had reached modest levels of portal use. Increased portal use has been associated with younger age, white race, and higher socioeconomic status. Most cancer patients used portals to look up testing results and provide notes, but had difficulty in interpreting the results appropriately.

Conclusions: Our study adds to the growing evidence that patient portals play a significant role in promoting self-management in cancer survivors. Additional studies are needed to determine factors influencing portal use, so effective interventions can be developed to enhance portal use.

DOI: 10.29245/2578-2967/2018/6.1154 View / Download Pdf

James E. Trosko

Department of Pediatrics/Human Development, College of Human Medicine, Michigan State University, East Lansing, Michigan, USA

While the concept of “precision medicine” is not new, sophisticated technologies have led to a view that the data generated will provide individuals, physicians and public policy-makers with the information required to predict, intervene and protect against many diseases. However, without understanding of the underlying molecular mechanisms, such as the mutagenicity, cytotoxicity or epigenetic alterations, induced by agents to which a human has been exposed, and with pathogenic events, such as birth defects, cardiovascular disease, cancer, immune responses, and reproductive or neurological diseases, there will be no “precision”. The aim of this “Commentary” is that, while mutations and cell death contribute to human diseases, including cancers, the toxicity of chemicals is primarily due to epigenetic effects on human organ-specific adult stem cells. From the perspective of biological evolution, the transition from single- to multi-cellular organisms, along with the generation of new genes and cellular processes, led to the evolution of Homo sapiens and “cultural evolution”. This transition has created a “collision” of the slow biological evolution of genes that are important for survival in various environments, with extremely fast cultural evolution. This has occurred when cultural evolution has provided new means of migration for both people and foods, as well as new methods of agriculture and food production/distribution/processing. The population explosion, ecological alterations, global climate changes, and worldwide economic disparities all have a bearing on how the increases in median life span and the incidence of chronic metabolic diseases are managed in the face of globally limited healthcare resources.

DOI: 10.29245/2578-2967/2018/6.1152 View / Download Pdf

Joseph A. Di Como1, Christina W. Lee2, Sharon M. Weber2*

Department of Surgery, Conemaugh Memorial Medical Center, Johnstown PA, USA

Department of Surgery, University of Wisconsin, Madison WI, USA

DOI: 10.29245/2578-2967/2018/6.1143 View / Download Pdf

Igor M. A. Melo, Eliane A. Ribeiro, Renata A. Canevari*

Laboratório de Biologia Molecular do Câncer, Instituto de Pesquisa & Desenvolvimento (IP&D), Universidade do Vale do Paraíba (UNIVAP), São José dos Campos, São Paulo, Brasil

Human papillomavirus (HPV) infection is the most common sexually transmitted disease worldwide and several studies have proven the close relationship between HPV and the development of cervical cancer. Several tests are currently performed for early and reliable diagnosis, in which the cervical cytology evaluation by the Papanicolaou method is highlighted. However, errors in the collection and misinterpretation of cell differentiation degree in smear by the pathologist result in incorrect or inaccurate results. Considering these points, it is of utmost importance to develop new technologies that perform accurate and reliable diagnosis and that present financial advantages and accessibility. Currently, molecular biology assays are excellent detectors of viral DNA, but it presents disadvantages, such as the need for high financial resources to gain access. Therefore, this review has the objective of highlighting the main diagnostic techniques that are already being used, such as specific kits for the detection of high-risk HPVs, or methodologies that are still in the study phase, but which already present good results, such as the application of physical FTIR spectroscopy principles and ultrasensitive biosensors.

DOI: 10.29245/2578-2967/2018/6.1132 View / Download Pdf

Maryam Ghotbaddini, Vivian Moultrie, Joann B. Powell*

Clark Atlanta University- Center for Cancer Research and Therapeutic Development 223 James P. Brawley Drive Atlanta, Georgia, USA

Research on the aryl hydrocarbon receptor (AhR) has largely focused on its activation by various environmental toxins. Consequently, only limited inferences have been made regarding its constitutive activity in the absence of an exogenous ligands. Evidence has shown that AhR is constitutively active in advanced prostate cancer cell lines which model castration resistant prostate cancer (CRPC). CRPC cells can thrive in an androgen depleted environment. However, AR signaling still plays a major role. Although several mechanisms have been suggested for the sustained AR signaling, much is still unknown. Recent studies suggest that crosstalk between constitutive AhR and Src kinase may sustained AR signaling in CRPC. AhR forms a protein complex with Src and plays a role in regulating Src activity. Several groups have reported that tyrosine phosphorylation of AR protein by Src leads to AR activation, thereby promoting the development of CRPC. This review evaluates reports that implicate constitutive AhR as a key regulator of AR signaling in CRPC by utilizing Src as a signaling intermediate.

DOI: 10.29245/2578-2967/2018/5.1136 View / Download Pdf

Xiao Wang*, Yin Zhang, Ning Yue, Ke Nie

Department of Radiation Oncology, Rutgers-Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ, USA

In treating locally advanced non-small-cell lung cancer (NSCLC), radio-tolerance of the normal lung often limits the amount of dose that can be delivered to the primary cancer site. Radiation-related pneumonitis (RP) and other normal lung tissue complications have a significant impact on clinical outcome and patient quality of life. How to minimize treatment side effects while achieving desirable local control of lung cancers has been a continuous challenge.

Functional imaging-guided radiotherapy, which can achieve a local boost of primary cancer site or functional avoidance of normal organs, has been increasingly utilized in clinics. Various imaging approaches have been employed to achieve functional imaging guidance and implemented in different treatment regimens. There are several on-going clinical trials aiming to evaluate the clinical outcomes that are utilizing functional imaging-guided photon radiation to spare the high functioning portions of the lungs. The main applications of functional imaging-guided radiotherapy in the management of NSCLC patients will be discussed in this review.

DOI: 10.29245/2578-2967/2018/5.1150 View / Download Pdf

Sung Wan Kim1,2*, Joung-Pyo Nam1,2, Soyoung Kim1,2, Yong Kiel Sung1,2,3

Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, Utah 84112, USA

Center for Chemically Controlled Delivery, University of Utah, Salt Lake City, Utah 84112, USA

Department of Chemistry, Dongguk University, Phildong-ro 1 Gil, Chung-gu, Seoul 04620, Korea

The design of a gene delivery system requires a complete understanding of the interaction between targeting cell and delivery systems. The poly(cystaminebis- (acrylamide)-diaminohexane) (poly(CBA-DAH)) has been confirmed as a bio-reducible efficient delivery carrier among the various systems. Poly(ethylenimine) (PEI, 1.8?kDa) was conjugated to poly(CBA-DAH) via a disulfide bond. The PEI conjugated poly(CBA-DAH) (PCDP) was able to bind with pDNA at a very low molecular weight ratio and form the polyplexes with nano-size and positive surface charge. To confirm the transfection efficiency, the plasmid DNA encodes with the luciferase reporter gene and green fluorescent protein reporter gene have made to use a bio-reducible efficient gene delivery. The PCDP polyplexes show 10 times higher gene transfection efficiency than Lipofectamine® polyplexes in bio-mimic in vivo condition. It has been reviewed that the bio-reducible PEI(1.8kDa) conjugated poly(CBA-DAH) is finally concluded as an efficient gene delivery carrier.

DOI: 10.29245/2578-2967/2018/5.1145 View / Download Pdf

Ting-Hsuan Yang1,2, Ren-Jun Hsu2, Wen-Hsin Huang1, An-Rong Lee1*

School of Pharmacy, National Defense Medical Center, No. 161, Section 6, Mingchuan East Road, Taipei 11490, Taiwan

Tri-Service General Hospital Biobank, No.325, Sec. 2, Chenggong Rd. Taipei 11490, Taiwan

Cancer cells are characterized by uncontrolled proliferation after escaping from inherent physiological constraints on growth and survival and by destructive invasion of the healthy surrounding tissues. Many kinases involved in signal transduction are overactive in malignant tumor cells. Thus, pharmacotherapeutic interventions targeting kinases responsible for signal transduction of cancer hallmarks have become promising in developing novel anticancer agents. Pyrrole indolin-2-one (or pyrrole oxindole, 1), a lead scaffold of kinase inhibitors, is used for anti-angiogenesis via inhibiting vascular endothelial growth factor receptors (VEGFs) and platelet-derived growth factor receptors (PDGFRs). The kinase selectivity and inhibitory activity of pyrrole indolin-2-one 1 can be significantly influenced through structural modifications. This mini-review provides a detailed overview of structural modification of pyrrole indolin-2-one derivatives for the development of novel kinase inhibitors.

DOI: 10.29245/2578-2967/2018/5.1153 View / Download Pdf

Xue Li1, Chun Yang2, Xiangyan Ruan1, Stéphane Croteau2, Pierre Hardy2*

1Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China

2Departments of Medicine, Pediatrics, Pharmacology and Physiology, University of Montreal, Montreal, Quebec, Canada

Despite all our efforts, breast cancer remains a major public health problem threatening women’s health all around the world. The morbidity of breast cancer is rising in most countries and is going to rise further over the next 20 years. Hormone treatment is widely used and it is the most efficient method of reducing menopausal symptoms or preventing abortion and pregnancy. However, multiple studies have demonstrated that hormones, especially synthetic progesterone, remain an indisputable risk factor for breast cancer. MicroRNAs are a group of endogenous small non-coding single strand RNAs which play regulatory roles in the initiation, development, and progression of different types of cancer. Evidence from multiple sources indicates that microRNA-181a exerts anti-breast cancer effects by inducing cancer cell death and preventing tumor invasion, infiltration and metastasis, etc. Our recent studies revealed that microRNA-181a not only suppresses breast cancer MCF-7 cell growth but also abrogates progestin-provoked cell growth. In this review, several interesting aspects of hormone replacement therapy and the role of microRNA-181a during progestin treatment are discussed.

DOI: 10.29245/2578-2967/2018/5.1147 View / Download Pdf

Ofer Purim1*, Aron Popovtzer2, Ron Epelbaum3

1Oncology Institute, Assuta Ashdod Academic Hospital, Ashdod, Israel

2Institute of Oncology, Davidoff Center, Rabin Medical Center, Petah Tikva, Israel, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

3Department of Oncology, Rambam Health Care Campus, Haifa, Israel

In the last 20 years, cancer treatment has witnessed a paradigm shift with the advent of modern targeted therapies. Still, at present, targeted therapies, despite being very effective, are only relevant for a minority of patients, whereas the majority of patients are still being offered cytotoxic drugs. The goal of this mini-review is to describe the clinical utility of tumor multi-panel molecular profiling (MMP) to guide treatment decisions (primarily chemotherapies but also targeted therapies) in patients with solid tumors and the evidence supporting this approach, focusing on the Caris Molecular Intelligence (CMI) MMP. The evidence suggests that MMP is a practical, implementable tool that can be used to personalize treatment (including that of chemotherapies), increasing the likelihood of response and sparing patients from unnecessary toxicity associated with ineffective therapies. MMP provides the ability to offer therapy to patients in later lines, particularly for those who have already failed multiple lines of therapy and exhausted the standard therapy options (by suggesting therapies which may be used off-label). Furthermore, the evidence indicates that MMP-guided therapy favorably impacts both progression-free survival and overall survival. As the current data consist of mainly retrospective studies, prospective trials are warranted to strengthen the evidence.

DOI: 10.29245/2578-2967/2018/4.1149 View / Download Pdf

Frank E Mott1*, Ruth L. Sacks2

1Thoracic and Head/Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Texas, USA

2University of Texas MD Anderson Cancer Center, Texas, USA

Standard treatment of locally advanced nasopharyngeal carcinoma is patterned after the Intergroup 0099 trial with concurrent cisplatin with radiotherapy, followed by consolidation chemotherapy. This remains the guideline recommended standard. With the wider use of intensity modulated radiotherapy and the incorporation of taxanes in the chemotherapy regimen, many oncologists are increasingly using an induction approach with chemotherapy followed by concurrent chemoradiotherapy. Induction chemotherapy is not considered a standard approach despite studies showing efficacy and tolerability. In this mini-review, we summarize the data from trials and reviews of induction therapy and argue for its recognition as a viable standard option for patients with locally advanced nasopharyngeal carcinoma.

DOI: 10.29245/2578-2967/2018/4.1146 View / Download Pdf

Rania Gaber1,2,3, Torsten Goldmann1,3*

1Pathology of the University of Lübeck and the Research Center Borstel, Site Borstel, Clinical and Experimental Pathology, Borstel, Germany

2Department of Pathology, Faculty of Medicine, Alexandria University, Alexaandria, Egypt

3Airway Research Center North (ARCN), Member of the German Center for Lung Research, Germany

Epidermal growth factor receptor (EGFR) is a predictive biomarker in many solid cancers including non-small cell lung carcinoma (NSCLC). Patients’ responsiveness to therapy is based on the prior determination of EGFR status. Many techniques were used to detect the potential predictive biomarker and considered as gold standards based on molecular genetic techniques as direct sequencing and polymerase chain reaction (PCR). Immunohistochemistry (IHC) using EGFR mutation-specific antibodies were generated as an alternative simple tool to identify EGFR status and its response to tyrosine kinase inhibitors (TKIs). EGFR gene copy number and wild-type EGFR are other parameters which determine the response to TKIs. The aim of this mini-review is to analyze the studies which investigated the IHC EGFR mutation-specific antibodies, in lung adenocarcinoma (ADC), to determine its accuracy and reliability as a pre-selection tool for candidate patients for TKIs therapy as well as the interplay with other EGFR biomarkers which are EGFR gene copy number and the wild-type EGFR in lung NSCLC. The later determine the response to TKIs and their detection methodology is standardized making them good candidates for comparison with the EGFR-mutation.

DOI: 10.29245/2578-2967/2018/4.1140 View / Download Pdf

Edward J. Macarak, Joel Rosenbloom*

The Joan and Joel Rosenbloom Research Center for Fibrotic Diseases, Department of Dermatology and Cutaneous Biology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA

Radiation induced fibrosis (RIF) is a common morbidity in patients being treated for cancer with radiation. Off-target effects result in intense inflammatory responses which ultimately results in the generation of extracellular matrix (ECM) producing myofibroblasts which mediate a progressive fibrosis resulting in scarring and organ and tissue dysfunction. Unfortunately, currently, there are no effective therapies to block the excess accumulation of ECM. We have previously reported on the use of trametinib, a MEK inhibitor, to essentially block the formation of abdominal adhesions in a mouse model of cecal abrasion. Using this drug in the mouse model, the complete trans-differentiation of precursor cells into ECM-producing myofibroblasts was blocked. Trametinib is a potentially powerful drug to thwart organ and tissue fibrosis in RIF because it has a potential dual function in that it may block RIF as well as prevent radiation-resistance. Given the intractability of RIF, trametinib should be considered for more extensive testing.

DOI: 10.29245/2578-2967/2018/4.1144 View / Download Pdf

Erika Spaeth1*, Athena Starlard-Davenport2, Richard Allman3

1Phenogen Sciences Inc, Charlotte, NC 28269, USA

2Department of Genetics, Genomics and Informatics, University of Tennessee Health Science Center, Memphis, TN 38163, USA

3Genetic Technologies, Ltd, Fitzroy, VIC 3065, Australia

Breast cancer remains the second leading cause of cancer death among women and is the most commonly diagnosed cancer in women. Breast cancer risk assessment has been clinically available for nearly 30 years yet is under-utilized in practice for multiple reasons. Incorporation of polygenic risk as well as breast density measurements, promise to increase the accuracy of risk assessment. With that comes the hope that both prevention and screening become more personalized and thus more effective. Incidence rates have been static over the past 15 years and have even increased slightly in African American and Asian/Pacific Islander populations despite the robust data on breast cancer risk reduction measures that exist. Current challenges in reducing breast cancer incidence begin with robust data curation that allows for appropriate risk stratification across our multiethnic population and conclude with the implementation of prevention strategies within our fractured healthcare system.

DOI: 10.29245/2578-2967/2018/4.1137 View / Download Pdf

Wangqian Zhang1, Cun Zhang2*

1,2State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, Fourth Military Medical University, Xi’an, China, 710032

DOI: 10.29245/2578-2967/2018/3.1135 View / Download Pdf

Samantha Thifani Alrutz Barcelos1*, Adriana Zanoni Dotti2, Juliano Emanuel Herrera3, Leandra Náira Zambelli Ramalho4

1Medical resident in hepatology HCPA

2Gastroenterologist in São Paulo-SP

3Cardiologist IC-FUC

4Associate Professor of the Pathology Department FMRP-USP

Endocrine tumors of chromaffin cells are most frequent in the gastrointestinal tract. Moreover, they are the ones of best prognosis. Promising results have been recorded for liver transplantations in case of metastatic gastrointestinal neuroendocrine tumors. We exhibit a case report of a patient presenting dyspeptic and carcinoid syndrome, hepatic metastasis diagnosis and primary tumor of the ileum detected through scheduled hepatectomy. Liver transplantation was the chosen therapy given the impossibility of hepatectomy due to hepatic metastatic involvement. Liver transplantation is a healing therapeutic option for patients with gastrointestinal neuroendocrine tumor in case of unresectable hepatic metastases. It assures more than 50% survival within 5 years in case of primary tumors in the small intestine. Survival is longer in case of liver transplantation after primary tumor resection than in usual palliative treatments such as embolization and chemoembolization.

The article points out the importance of the therapeutic management of the neuroendocrine gastrointestinal metastatic tumor, with emphasis on performing liver transplantation as a possible curative treatment.

DOI: 10.29245/2578-2967/2018/3.1124 View / Download Pdf

Steven S. Coughlin, PhD, MPH1,2*, Valerie Williams, PT, PhD, DPT, OCS3, Nicole Moore, MS, RD, LD1, Deborah Bowen, PhD4, Judith Anglin, PhD, RD, LD, FAND1, Nadine Mansour, MD, MPH1, Gianluca De Leo, PhD, MBA1

1Department of Clinical and Digital Health Sciences, Augusta University, Augusta, GA

2Research Service, Charlie Norwood Veterans Administration Medical Center, Augusta, GA

3Physical Therapy Department, Augusta University, Augusta, GA

4University of Washington School of Medicine, Seattle, WA

Introduction: Several studies have provided important information about health conditions and other challenges faced by women diagnosed with breast cancer and how they can improve their quality of life and reduce their risk of cancer recurrence. Although African American and Hispanic breast cancer patients have a poorer survival than their white counterparts, few studies have compared the experiences of African American, Hispanic, and non-Hispanic white breast cancer survivors.

Objectives: To facilitate collaborative studies on breast cancer survivorship in a multicultural population, including future intervention research on nutrition, and physical activity, and clinical substudies.

Methods: This cohort study consists of a postal survey of up to 1,000 women with a history of a breast cancer diagnosis who reside in Augusta-Richmond County, Georgia, USA, and a repeat survey in 4 to 5 years to obtain longitudinal data. The follow-up survey in 4 to 5 years will allow for longitudinal changes in health to be assessed.

Conclusion: The survey will provide a comprehensive picture of the health of breast cancer survivors, across the lifespan, in a large Southern city. A broad range of health issues will be addressed including physical activity, diet, nutrition, personal and family history of cancer, quality-of-life, psychosocial concerns, and beliefs about cancer recurrence risk reduction through lifestyle changes. Through its longitudinal design, the study will also provide important information about changes in physical and mental health as breast cancer survivors advance in age.

DOI: 10.29245/2578-2967/2018/3.1131 View / Download Pdf

Alondra M. Ortiz Ortiz5, Olivia George6, Khalaf Jasim1,2,7, Andre J. Gesquiere1,2,3,4*

1NanoScience Technology Center, University of Central Florida, Orlando, FL 32826, USA

2Department of Chemistry, University of Central Florida, Orlando, FL 32816, USA

3Department of Materials Science and Engineering, University of Central Florida, Orlando, FL 32816, USA

4The College of Optics and Photonics (CREOL), University of Central Florida, Orlando, FL 32816, USA

5Department of Mechanical Engineering, University of Puerto Rico, Mayaguez Campus, Mayaguez 00681-9000, Puerto Rico

6Department of Chemical Engineering, University of Tennessee at Chattanooga, Chattanooga, TN 37403, Tennessee

7Department of Chemistry, University of Tikrit, Tikrit, Salah Al-Din PO Box 42, Iraq

Many types of cancers require elevated levels of Reactive Oxygen Species (ROS) for uncontrolled proliferation. However, this also makes tumor cells more susceptible to ROS induced cell death by additional oxidative stress caused by external stimuli. By selectively targeting cancer cells and tumors that exhibit high levels of ROS with nanotechnology-based materials to trigger further elevation of ROS therapeutic possibilities become available. Specifically, light-activated treatment through Photodynamic Therapy (PDT) has been demonstrated as a feasible approach with Photophryn as the leading FDA approved sensitizer. However, such small molecule sensitizers do still have significant hurdles to overcome, including poor solubility, non-targeted delivery, and low absorption of light. In this mini review, recent advances in the development of Conjugated Polymer Nanoparticles (CP-NPs) solving these issues are discussed, including amplified ROS generation, tumor targeting, theranostic capabilities, and multimodal CP-NPs. We also give an outlook towards further needs in CP-NP development for clinical application.

DOI: 10.29245/2578-2967/2018/3.1134 View / Download Pdf